- Home
- NU vs REGN Comparison
NU vs REGN Comparison
Compare NU & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NU | REGN |
|---|---|---|
| Founded | 2013 | 1988 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.7B | 77.5B |
| IPO Year | 2016 | 1995 |
Fundamental Metrics
Financial Performance| Metric | NU | REGN |
|---|---|---|
| Price | $13.76 | $756.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 24 |
| Target Price | $17.84 | ★ $819.54 |
| AVG Volume (30 Days) | ★ 58.9M | 483.3K |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.50% |
| EPS Growth | N/A | ★ 8.19 |
| EPS | N/A | ★ 41.48 |
| Revenue | N/A | ★ $5,872,227,000.00 |
| Revenue This Year | $185.03 | $11.88 |
| Revenue Next Year | $20.37 | $10.31 |
| P/E Ratio | $33.29 | ★ $18.25 |
| Revenue Growth | N/A | ★ 20.82 |
| 52 Week Low | $9.01 | $476.49 |
| 52 Week High | $18.98 | $821.11 |
Technical Indicators
Market Signals| Indicator | NU | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 36.00 | 48.39 |
| Support Level | $13.53 | $750.69 |
| Resistance Level | $14.06 | $788.69 |
| Average True Range (ATR) | 0.41 | 15.76 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 9.91 | 47.83 |
Price Performance
Historical ComparisonAbout NU Nu Holdings Ltd.
Nu Holdings Ltd provides digital banking services. It offers several financial services such as Credit cards, Personal accounts, Investments, Personal Loans, Insurance, Mobile payments, Business Accounts, and Rewards. The company earns the majority of its revenue in Brazil.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).